Hill-Rom (NYSE:HRC) posted its quarterly earnings data on Friday. The medical technology company reported $1.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.12, MarketWatch Earnings reports. Hill-Rom had a net margin of 8.19% and a return on equity of 20.54%. The company had revenue of $759.20 million during the quarter, compared to analysts’ expectations of $750.90 million. During the same period in the prior year, the company posted $1.32 earnings per share. Hill-Rom’s revenue for the quarter was up 2.8% compared to the same quarter last year.
NYSE:HRC traded up $3.41 during trading hours on Friday, reaching $90.19. The company had a trading volume of 45,428 shares, compared to its average volume of 551,846. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 1.17 and a beta of 0.89. Hill-Rom has a twelve month low of $75.21 and a twelve month high of $98.96.
A number of large investors have recently bought and sold shares of HRC. Vigilant Capital Management LLC acquired a new stake in Hill-Rom in the second quarter worth $109,000. Flagship Harbor Advisors LLC acquired a new stake in Hill-Rom in the second quarter worth $173,000. CIBC Asset Management Inc acquired a new stake in Hill-Rom in the second quarter worth $203,000. CAPROCK Group Inc. acquired a new stake in Hill-Rom in the third quarter worth $211,000. Finally, Hartford Investment Management Co. acquired a new stake in Hill-Rom in the second quarter worth $215,000. Institutional investors and hedge funds own 81.01% of the company’s stock.
Several equities research analysts have recently weighed in on HRC shares. KeyCorp increased their price objective on shares of Hill-Rom from $97.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 17th. Raymond James increased their price objective on shares of Hill-Rom from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, July 30th. Northcoast Research reiterated a “buy” rating and set a $104.00 price objective on shares of Hill-Rom in a research report on Tuesday, July 31st. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday, July 31st. Finally, Zacks Investment Research cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $99.44.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
See Also: How can you know how many shares are floating?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.